Eton Pharmaceuticals (NASDAQ:ETON) Insider Sells $235,935.00 in Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider Ipek Erdogan-Trinkaus sold 3,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $67.41, for a total value of $235,935.00. Following the sale, the insider directly owned 4,081 shares of the company’s stock, valued at $275,100.21. This represents a 46.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Eton Pharmaceuticals Trading Up 4.0%

ETON stock traded up $2.48 during mid-day trading on Friday, reaching $63.93. The company’s stock had a trading volume of 600,888 shares, compared to its average volume of 589,512. Eton Pharmaceuticals, Inc. has a 12 month low of $14.27 and a 12 month high of $70.64. The company has a current ratio of 1.79, a quick ratio of 1.58 and a debt-to-equity ratio of 0.13. The business’s 50 day moving average price is $55.26 and its 200 day moving average price is $37.71. The company has a market cap of $1.84 billion, a price-to-earnings ratio of 42.34 and a beta of 0.89.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.19. The firm had revenue of $57.93 million for the quarter, compared to analysts’ expectations of $41.98 million. Eton Pharmaceuticals had a return on equity of 104.82% and a net margin of 35.35%. On average, equities research analysts predict that Eton Pharmaceuticals, Inc. will post 1.54 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ETON. Hilton Head Capital Partners LLC bought a new stake in shares of Eton Pharmaceuticals during the third quarter valued at approximately $26,000. Global Retirement Partners LLC acquired a new position in shares of Eton Pharmaceuticals during the third quarter worth approximately $26,000. Morse Asset Management Inc bought a new position in shares of Eton Pharmaceuticals in the 3rd quarter worth $35,000. Toth Financial Advisory Corp bought a new position in shares of Eton Pharmaceuticals in the 2nd quarter worth $43,000. Finally, Sterling Capital Management LLC lifted its holdings in shares of Eton Pharmaceuticals by 845.7% in the 3rd quarter. Sterling Capital Management LLC now owns 889 shares of the company’s stock worth $46,000 after purchasing an additional 795 shares in the last quarter. Institutional investors own 27.86% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ETON. B. Riley Financial boosted their target price on shares of Eton Pharmaceuticals from $70.00 to $81.00 and gave the company a “buy” rating in a research report on Tuesday, November 10th. Zacks Research cut shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 10th. Canaccord Genuity Group raised their price target on shares of Eton Pharmaceuticals from $68.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Craig Hallum reaffirmed a “buy” rating and issued a $78.00 price target on shares of Eton Pharmaceuticals in a research note on Thursday, October 15th. Finally, HC Wainwright upped their price objective on shares of Eton Pharmaceuticals from $70.00 to $80.00 and gave the company a “buy” rating in a report on Friday, November 6th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $79.75.

About Eton Pharmaceuticals

Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited treatment options. Its work includes bringing new medicines and reformulated or otherwise specialized drug products to market. The company’s products include Alkindi Sprinkle, a hydrocortisone granule formulation used to treat adrenal insufficiency, and Eprontia, an oral solution of topiramate used to treat certain seizure disorders and prevent migraines.